CASI Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de CASI Pharmaceuticals' es Wei-Wu He, nombrado en Apr 2019, tiene una permanencia de 12.17 años. posee directamente un 5.29% de las acciones de la empresa, con un valor de $1.58M. La antigüedad media del equipo directivo y de la junta directiva es de 4.6 años y 8.8 años, respectivamente.
Información clave
Wei-Wu He
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 5yrs |
| Participación del CEO | 5.3% |
| Permanencia media de la dirección | 4.6yrs |
| Promedio de permanencia en la Junta Directiva | 8.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?
Mar 16Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth
Feb 18
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?
Jan 23Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?
Dec 28CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer
Dec 23CASI Pharmaceuticals appoints Weihao Xu as CFO
Dec 16Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%
Dec 02The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares
Nov 27Casi Pharmaceuticals jumps 6% after CEO buys 227.5K shares
Nov 25Juventas initiates registration study for CNCT19
Nov 19CASI Pharmaceuticals EPS misses by $0.08, beats on revenue
Nov 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | n/a | n/a | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$10m | US$322k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$819k | US$578k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$47m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$9m | US$424k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$43m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$32m |
| Dec 31 2018 | US$6m | n/a | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$781k | n/a | -US$11m |
Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Wei-Wu es razonable en comparación con empresas de tamaño similar en el mercado US.
Compensación vs. Ingresos: La compensación de Wei-Wu ha aumentado mientras la empresa no es rentable.
CEO
Wei-Wu He (58 yo)
5yrs
Permanencia
US$9,665,359
Compensación
Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 5yrs | US$9.67m | 5.29% $ 1.7m | |
| President | 4.6yrs | US$2.56m | 0.016% $ 4.9k | |
| Executive VP & Chief Medical Officer | 7yrs | US$1.18m | sin datos | |
| VP & Global Controller | 2.3yrs | sin datos | sin datos | |
| Chief Operating Officer | 6.1yrs | sin datos | sin datos | |
| General Counsel | 1.3yrs | sin datos | sin datos | |
| Chief Business Development Officer | no data | sin datos | sin datos | |
| Global Chief Commercial Officer | less than a year | sin datos | sin datos | |
| VP & Global Controller | no data | sin datos | sin datos |
4.6yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CASI se considera experimentado (4.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 12.2yrs | US$9.67m | 5.29% $ 1.7m | |
| Member of Scientific Advisory Board | 17.8yrs | sin datos | sin datos | |
| Independent Director | 11yrs | US$150.50k | sin datos | |
| Independent Director | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | 8.8yrs | sin datos | sin datos | |
| Independent Director | 1.1yrs | sin datos | sin datos | |
| Member of Clinical Advisory Board | 8.8yrs | sin datos | sin datos | |
| Independent Director | 8.3yrs | sin datos | sin datos |
8.8yrs
Permanencia media
56.5yo
Promedio de edad
Junta con experiencia: La junta directiva de CASI se considera experimentada (8.8 años de antigüedad promedio).